Physician

Guangquan Zhao, MD

According to 2025 Medicare claims, Guangquan Zhao, MD (NPI: 1710197314) practices medical oncology in the Longview-Kelso, WA market, with the plurality of this provider's patient population coming from Cowlitz, WA. This provider's primary affiliated billing organization is PEACEHEALTH (NPI: 1720056187; TIN: 910564987) and primary practice location at 98632-2310. Zhao is affiliated with the PeaceHealth Direct Contracting LLC (ACO ID: D0152), participating under the REACH model.

Zhao's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 192 traditional Medicare patients, billed 1,835 HCPCS/CPT codes, and received $120,488 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,333 prescription claims across 298 beneficiaries totaling $2,934,545 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 11 claims. Open Payments data shows 1 records totaling $15. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $131,761 and ending at $120,488. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $390,222 to $2,934,545. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	307	1,614	$131,761
2016	353	17,442	$257,872
2017	305	183,084	$1,237,543
2018	298	34,240	$409,867
2019	298	1,617	$117,986
2020	305	1,560	$110,170
2021	258	1,664	$168,771
2022	243	1,452	$158,143
2023	212	1,152	$119,078
2024	192	1,835	$120,488

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	131	1,015	$390,222
2016	111	514	$416,148
2017	77	491	$746,185
2018	175	848	$1,518,161
2019	206	1,496	$1,450,154
2020	248	1,659	$1,871,796
2021	259	1,568	$2,435,679
2022	277	1,725	$2,618,543
2023	312	2,269	$2,040,204
2024	298	2,333	$2,934,545

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	25	$28,778
2016	N/R	12	$15,291
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	24	$851
2021	N/R	N/R	N/R
2022	N/R	12	$481
2023	N/R	12	$512
2024	N/R	11	$436

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	58	58	$136
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	123	810	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	100	192	$69
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	12	14	$24
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	138	675	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	58	1,740	$794,680
Lenalidomide	Lenalidomide	26	707	$337,203
Verzenio	Abemaciclib	21	588	$301,930
Revlimid	Lenalidomide	11	280	$185,160
Brukinsa	Zanubrutinib	12	360	$180,093

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0443	Portable oxygen contents, gaseous, 1 month's supply = 1 unit	N	N/R	11	$436

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$15	Aveo Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Guangquan Zhao, MD?

Tedicare shows public-source Medicare data for Guangquan Zhao, MD (NPI 1710197314), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Guangquan Zhao, MD have ACO affiliation data?

Guangquan Zhao, MD is shown with ACO affiliation data for PeaceHealth Direct Contracting LLC (REACH, ACO ID D0152).

What billing organization is linked to Guangquan Zhao, MD?

Guangquan Zhao, MD is linked to PEACEHEALTH (billing NPI 1720056187) in the available physician profile data.

Does Guangquan Zhao, MD have Open Payments data?

Guangquan Zhao, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.